Tâmila Siminski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tâmila Siminski has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Luiz Braga
Department of Chemistry Federal University of Santa Catarina – UFSC Florianópolis Santa Catarina 8040‐900 Brazil
1 shared publication - Ariane Zamoner
Department of Biochemistry, Graduate Program, Federal University of Santa Catarina, Florianópolis, SC, Brazil
1 shared publication - Cynthia Pádua
Departamento de Bioquímica, Laboratório de Bioquímica Experimental (LABIOEX) Universidade Federal de Santa Catarina (UFSC) Florianópolis Santa Catarina Brazil
1 shared publication - Daniela Coelho dos Santos
Post-Graduate Program in Biochemistry and Bioprospection, Laboratory of Oral Microbiology, Pelotas Dental School, Federal University of Pelotas, Pelotas, RS, Brazil
1 shared publication - Danilo Wilhelm Filho
Department of Ecology and Zoology, Center for Biological Sciences (CCB), Federal University of Santa Catarina, Florianópolis 88040-900, SC, Brazil
1 shared publication - Fabiana Ourique
Universidade Federal de Juiz de Fora
1 shared publication
Latest Publications
- 30 October 2020
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 35 (3) , e22663
Apoptosis oxidative damage‐mediated and antiproliferative effect of selenylated imidazo[1,2‐a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo
Imidazo[1,2‐a]pyridines (IP) and organoselenium compounds have been widely exploited in medicinal chemistry due to their pharmacological activities. Hepatocellular carcinoma (HCC) has few treatment options, and unfortunately, the prognosis is poor. Thus, the development of novel therapeutic drugs is urgent. The present study aimed at evaluating the antitumor mechanism of selenylated IP against HepG2 cells and in vivo. The selenylated IP named IP‐Se‐06 (3‐((2‐methoxyphenyl)selanyl)‐7‐methyl‐2‐phenylimidazol[1,2‐a]pyridine) showed high cytotoxicity against HepG2 cells (half‐maximal inhibitory concentration [IC50] = 0.03 µM) and selectivity for this tumor cell line. At nontoxic concentration, IP‐Se‐06 decreased the protein levels of Bcl‐xL and increased the levels of p53, leading to inhibition of cell proliferation and apoptosis. This compound decreased the level of extracellular signal‐regulated kinase 1/2 protein and changed the levels of proteins involved in the drive of the cell cycle, tumor growth, and survival (cyclin B1, cyclin‐dependent kinase 2). In addition, IP‐Se‐06 decreased the number of cells in the S phase. In addition, IP‐Se‐06 led to increased generation of reactive oxygen species, changed antioxidant defenses, and caused DNA fragmentation. Finally, IP‐Se‐06 significantly inhibited the growth of Ehrlich ascites tumors in mice, increased survival time, and inhibited angiogenesis. Therefore, IP‐Se‐06 may be an important compound regarding the development of a therapeutic drug for HCC treatment.
- 30 October 2020
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 35 (3) , e22663
Apoptosis oxidative damage‐mediated and antiproliferative effect of selenylated imidazo[1,2‐a]pyridines on hepatocellular carcinoma HepG2 cells and in vivo
Imidazo[1,2‐a]pyridines (IP) and organoselenium compounds have been widely exploited in medicinal chemistry due to their pharmacological activities. Hepatocellular carcinoma (HCC) has few treatment options, and unfortunately, the prognosis is poor. Thus, the development of novel therapeutic drugs is urgent. The present study aimed at evaluating the antitumor mechanism of selenylated IP against HepG2 cells and in vivo. The selenylated IP named IP‐Se‐06 (3‐((2‐methoxyphenyl)selanyl)‐7‐methyl‐2‐phenylimidazol[1,2‐a]pyridine) showed high cytotoxicity against HepG2 cells (half‐maximal inhibitory concentration [IC50] = 0.03 µM) and selectivity for this tumor cell line. At nontoxic concentration, IP‐Se‐06 decreased the protein levels of Bcl‐xL and increased the levels of p53, leading to inhibition of cell proliferation and apoptosis. This compound decreased the level of extracellular signal‐regulated kinase 1/2 protein and changed the levels of proteins involved in the drive of the cell cycle, tumor growth, and survival (cyclin B1, cyclin‐dependent kinase 2). In addition, IP‐Se‐06 decreased the number of cells in the S phase. In addition, IP‐Se‐06 led to increased generation of reactive oxygen species, changed antioxidant defenses, and caused DNA fragmentation. Finally, IP‐Se‐06 significantly inhibited the growth of Ehrlich ascites tumors in mice, increased survival time, and inhibited angiogenesis. Therefore, IP‐Se‐06 may be an important compound regarding the development of a therapeutic drug for HCC treatment.